X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for the treatment of HIV-associated tuberculosis.
Lead Product(s): Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Tivicay
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ViiV Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Lead Product(s): Rifapentine,Isoniazid
Therapeutic Area: Infections and Infectious Diseases Product Name: Rifapentine/Isoniazid-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Unitaid
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
